OpusPoint Partners: Successfully Melding the Worlds of Finance and Biotechnology
OpusPoint Partners through the guidance of its co-founders, Michael Weiss and Lindsay Rosenwald, M.D., are indisputably bringing about transformational biotechnology and life science companies to the forefront. The company’s investment in and mentoring of these budding biotech companies is the first step in making new discoveries that will make waves in the healthcare sector and ultimately lead to the betterment of human health.
Dr. Rosenwald and Weiss founded OpusPoint Partners in 2009. Since the company’s inception the two men have been leading the way in biotech backing and mentoring. Both Rosenwald and Weiss are thoroughly competent in commencing, guiding, and funding life science and biotech companies as they have, individual from each other, pulled together numerous research biotech companies over the span of 20 years. It is their goal to ensure that those upcoming companies that show a spark for innovation get the opportunity to truly make their mark in the medical industry.
Lindsay Rosenwald has showcased his zeal for taking biotechnology beyond its current barriers in order to make significant progress toward changing the state of illness in the world through his previous development of Cougar Biotechnology Inc. This Los Angeles based biotech company’s main research concern is in the realms of cancer trials and treatment. Many of the findings and drug trials done by this biotech company have gained the respect and attention from researchers and investors alike. The companies most significant drug development was a potentially lifesaving drug that has shown promise in assisting those with in the later stages of prostate cancer. In 2009 Rosenwald moved on from Cougar Biotech and the company was acquired by Johnson & Johnson for nearly one billion dollars.
OpusPoint Partners has maintained its success since its inception; this is largely due to the company’s consistent policy toward sustaining its firm foundation of integrity. Lindsay Rosenwald fully comprehends the needs of investors, and places ethical business practices as priority when dealing with emergent biotech and life sciences companies. Transparency on all ends leads way to confident investing by individuals and corporations, and gives OpusPoint Partners an air of quality professionalism that is unmatched.
Since OpusPoint Partners is a biotech investing company built on the groundwork of ethical principles, it is viewed as a trusted company in which a variety of investors and researchers are clamoring to get involved with. Growth at OpusPoint Partners over the past two years has been exponential; currently the company is acting both as a mentor and as a financial force behind more than 20 budding biotech companies. With the aid of Dr. Lindsay Rosenwald these promising companies will be able to realize their medical research goals and quite possible make a monumental discovery for humanity.
Those intertwined with OpusPoint Partners goals can rest assure that their financial and advisory needs will be acknowledged. With Lindsay Rosenwald heading up the company investors feel secure about the dealings as Rosenwald is committed to providing honest analysis of ventures and offers investors minimized investing risks. OpusPoint Partners knack for investment growth is strongly evident in the company track record of exceeding yearly projections.
Dr. Lindsay Rosenwald makes OpusPoint Partners what it is today; the company is an embodiment of his skills, morals, and goals. Rosenwald’s educational background is ideally suited to what he is currently doing in his professional life. He has a B.S. in Finance from Pennsylvania State University and a M.D. from Temple University School of Medicine. In the past Rosenwald has successfully utilized his academic knowledge in two separate fields, biotechnology and Wall Street financing. In the past 17 years he has been the driving force behind the development and financing of more than 50 biotech companies.
Dr. Rosenwald is also a skilled money manager having managed the assets of both the Aries Fund (1994 to 2007) and the Orion Fund (2002 to 2006.) During the 2000 year alone he managed the allocation of investment funds over one billion dollars for the Aries Fund, this money alone was for investment in healthcare. The Orion Fund, which is dedicated to raising funds for the biotechnology industry also prospered with Lindsay Rosenwald’s assistance.
The central focus of OpusPoint Partners is to bring about innovations within the medical and healthcare industries by way of promoting biotech and life science firms who have a pioneering spirit mixed with sound ethical practices. This company stands above many others like it because of its ground-breaking ideals and strong commitment to integrity above profit. It is not hard in the medical and pharmaceutical world to find individuals who are not afraid to smudge the line of decency in order to reap excessive monetary rewards; OpusPoint Partners is a beacon of light among the crowd whose steadfast honesty in business dealings garner them much respect in the biotechnology sphere.
With Lindsay Rosenwald acting as a strong moral compass for OpusPoint Partners, the continued success of this life science and biotech investment company is unquestionable. This is because at all levels of the company, from the co-founders, employees, investors, and the associated biotech companies all adhere to the ethical standards set forth by OpusPoint Partners.
Beyond the exceptional moral business standards that both Michael Weiss and Dr. Lindsay Rosenwald continually sustain at OpusPoint Partners, they also bring a vast amount of combined experience to the company. Together the pair has in excess of 40 years working in the biotechnology and life science sectors. During the time previous to venturing on their combined business endeavor of OpusPoint Partners, both men individually have started up and found investors for a multitude of their own biotechnology companies.
The over 20 emergent biotechnology companies currently backed by OpusPoint Partners are under knowledgeable guidance from Lindsay Rosenwald. Over the first two years of OpusPoint Partners existence their roster of investors and biotech companies has grown steadily and more quickly than initially projected. This growth has produced positive returns to investors and has allowed OpusPoint Partners to make great strides in the area of medicine research and trials.
Lindsay Rosenwald maintains his activity in the biotechnology financing world in order to bring new investor into the fold and expand the reach of OpusPoint Partners. He currently sits on the Board of Directors for the Republican Jewish Coalition.
No related posts.